Clinical Evaluation of HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure in Japan

Heart Failure Clinical Trial

— HW005  

Official title:

Clinical Evaluation of the HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02091440
• Other study ID #: HW005/ Japan
• Status: Completed
• Phase: N/A
• Start date: March 2014
• Est. completion date: December 6, 2018

Study information

• Verified date: July 2019
• Source: Medtronic Cardiac Rhythm and Heart Failure
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the safety and effectiveness of the HW005 System in patients listed for cardiac transplantation with refractory, advanced heart failure at risk of death.

Description:

The primary endpoint is success at 180 days which is expressed as a simple proportion and defined as alive on the originally implanted HW005 or transplanted or explanted for recovery. Patients must survive 60 days post-explant for recovery to be considered successful. The primary endpoint is not statistically powered. The six eligible implanted cases will be evaluated as a proportion of success accompanied by a 95% exact confidence interval and presented alongside the ADVANCE results for visual comparison.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: December 6, 2018
• Est. primary completion date: March 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 65 Years

Eligibility

Inclusion Criteria:

1. Patients with irreversible end-stage heart failure of New York Heart Association (NYHA) class III or IV and a history of class IV who are eligible for heart transplantation.

2. Patients who are dependent on medication of inotropes or intra-aortic balloon pump (IABP).

3. Body Surface Area (BSA) =1.2 m2. In addition other factors may be taken into consideration, including chest size, abdominal fat (lack of abdominal fat may preclude a pump pocket) and any other physical characteristics that might be benefited by an intra-pericardial pump in a small person.

4. Patients who are aged less than 65 years of age.

5. Patients must be able to understand the limits and complications associated with the HW005 Ventricular Assist System.

6. Female patients of childbearing potential must agree on contraception for the duration of the study.

7. The patient or the legal representative has signed the informed consent form.

Exclusion Criteria:

1. Severe illness other than heart disease which would exclude cardiac transplantation.

2. Inadequate family/social support.

3. Active, uncontrolled infection despite appropriate antibiotic, antiviral or antifungal treatment.

4. Existence of any ongoing mechanical circulatory support (MCS) other than an IABP.

5. Prior cardiac transplant or cardiomyoplasty.

6. Acute myocardial infarction within 14 days of implant.

7. Uncorrected thrombocytopenia or generalized coagulopathy.

8. Intolerance to anticoagulant or antiplatelet therapies or any other peri- or postoperative therapy that the investigator may administer based upon the patient's health status.

9. Patients for whom the use of a left ventricular assist device (LVAD) is contraindicated due to an ongoing aortic/cardiac aneurysm, intraventricular septum rupture and/or use of a mechanical heart valve.

10. Etiology of heart failure is due to, or associated with, uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, active myocarditis or restrictive cardiomyopathy.

11. Patients with irreversible hepatic dysfunction.

12. Patients with irreversible renal dysfunction.

13. Pregnancy.

14. Patients with serious chronic obstructive pulmonary disease (COPD) (Forced Expiratory Volume in the first second (FEV1) < 50%).

15. Pulmonary vascular resistance is unresponsive (fixed) to pharmacologic manipulation as demonstrated by a pulmonary artery systolic pressure exceeding 60mmHg in conjunction with any one of the two following variables:

• Pulmonary vascular resistance is greater than 6 Woods Units or

• Transpulmonary gradient exceeds 15 mmHg

16. Cardiothoracic surgery within 14 days of implantation.

17. Peripheral vascular disease with rest pain or ischemic ulcers of the extremities.

18. Pulmonary embolus within three weeks of enrollment as documented by computed tomography (CT) scan or nuclear scan.

19. Patients have moderate to severe aortic insufficiency without plans for correction during pump implantation surgery. Correction may include aortic valve repair at the time of implant.

20. The patient who has advanced calcification in the ascending aorta and/or the descending aorta.

21. Serious right heart failure as defined by the anticipated need for right ventricular assist device (RVAD) support or extracorporeal membrane oxygenation (ECMO) at the time of screening.

22. Patients with severe central nervous system disorder or severe cerebral vascular disorder.

23. Patients with a history of drug intoxication, alcohol dependence.

24. Patients unwilling or unable to comply with study requirements.

25. Patients who refuse transfusion.

26. Patients who in the investigator judgement are deemed to be unsuitable as a subject.

27. Patients who are participating in another clinical trial involving investigational drugs or devices.

Related Conditions & MeSH terms

• Heart Failure

Intervention

Device:
• Implant of the HW005 Ventricular Assist System.
The HW005 Pump is in implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use.

Locations

Country	Name	City	State
Japan	Kyushu University Hospital	Fukuoka	Kyushu
Japan	National Cerebral and Cardiovascular Center Hospital	Osaka
Japan	Osaka University Hospital	Osaka
Japan	Tohoku University Hospital	Sendai	Tohoku
Japan	The University of Tokyo Hospital	Tokyo

Sponsors (1)

Lead Sponsor	Collaborator
Medtronic Cardiac Rhythm and Heart Failure

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Alive on the Implanted HW005 Ventricular Assist System or Transplanted or Explanted for Recovery at 180 Days	The primary endpoint is success at 180 days which is defined as alive on the originally implanted HW005 Ventricular Assist System or transplanted or explanted for recovery. Patients must survive 60 days post-explant for recovery to be considered successful.	180 days
Secondary	Number of Participants Alive on the Implanted HW005 Ventricular Assist System at 180 Days		180 days
Secondary	Incidence of All Serious Adverse Events (SAEs) and Unanticipated Adverse Device Effects (UADEs)	SAEs are defined as events that result in death, are life-threatening, result in permanent disability, require medical treatment to prevent permanent disability or require surgical intervention or hospitalization.; UADEs are defined as any serious adverse device effect which by its nature, incidence, severity or outcome has not been identified in the current version of the risk analysis report.; Events were categorized using the Japanese registry for Mechanically Assisted Circulatory Support (J-MACS) definitions.	Through study completion, an average of 44.5 months
Secondary	Incidence of All Device Failures and Device Malfunctions.	The device failures and malfunctions are the failures on pumping function due to thrombosis inside/outside of the implanted pump, the mechanical failures of the implanted components, the mechanical failures of the external components and the failures due to the user.; Events were categorized using the J-MACS definitions.	Through study completion, an average of 44.5 months
Secondary	Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Quality of Life Score at 6 and 24 Months	The KCCQ is a self-evaluation questionnaire for patients with heart failure to assess the severity of their symptoms how it may affect their lives. Scores range between 0 (worst) - 100 (best).; Values in the table were calculated as the value at Month 6 (180 days) minus Screening and at Month 24 (after FU completion) minus Screening.; The positive change in KCCQ score indicates an improvement in patient Quality of Life.	Screening, Month 6 (180 days) and Month 24 (after follow-up (FU) completion)
Secondary	Change in NYHA Patient Classification (Patient Functional Status) at 6 and 24 Months	The New York Heart Association (NYHA) Functional Classification places patients with heart failure in one of four categories based on how much they are limited during physical activity.; Class I (best): No limitation of physical activity.; Class II: Slight limitation of physical activity. Comfortable at rest.; Class III: Marked limitation of physical activity. Comfortable at rest.; Class IV (worst): Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest.; A shift from a higher class (e.g. Class IV) to a lower class (e.g. Class II) indicates an improvement in patient health and functional status.	Screening, Month 6 (180 days) and Month 24 (after FU completion)
Secondary	Change in Patient 6-minute Walk Distance (Patient Functional Status) at 6 and 24 Months	For the 6-minute walk test, the patient is asked to walk for 6 minutes. The total distance walked is measured.; Values in the table were calculated as the value at Month 6 (180 days) minus Screening and at Month 24 (after FU completion) minus Screening.; A positive change in 6-minute walk distance indicates an improvement in health and functional status.	Screening, Month 6 (180 days) and Month 24 (after FU completion)